Ironwood Pharmaceuticals, Inc.  

(Public, NASDAQ:IRWD)   Watch this stock  
Find more results for IRWD
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 11.65 - 17.11
Open     -
Vol / Avg. 0.00/912,613.00
Mkt cap 1.97B
P/E     -
Div/yield     -
EPS -1.24
Shares 125.91M
Beta 1.41
Inst. own 108%
Aug 3, 2015
Q2 2015 Ironwood Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 3, 2015
Ironwood Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 13, 2015
Ironwood Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2015
Q1 2015 Ironwood Pharmaceuticals Inc Earnings Call
May 5, 2015
Q1 2015 Ironwood Pharmaceuticals Inc Earnings Release
Mar 11, 2015
Ironwood Pharmaceuticals Inc at Barclays Healthcare Conference
Mar 2, 2015
Ironwood Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -114.83% -248.07%
Operating margin -97.01% -221.58%
EBITD margin - -205.45%
Return on average assets -41.70% -61.92%
Return on average equity -170.06% -299.14%
Employees 464 -
CDP Score - -


301 Binney St
CAMBRIDGE, MA 02142-1030
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on creating medicines that make a difference for patients. The Company’s lead product, linaclotide provides patients and healthcare practitioners with a treatment option for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), GI disorders that affect millions of sufferers across the world. Linaclotide is available to adult men and women suffering from IBS-C, or CIC, in the United States under the trademarked name LINZESS, and to adult men and women suffering from IBS-C in the European Union (the E.U.), under the trademarked name CONSTELLA. The Company’s partner Astellas initiated a double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with IBS-C.

Officers and directors

Bryan E. Roberts Ph.D. Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Peter M. Hecht Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Thomas Graney Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
Age: 50
Bio & Compensation  - Reuters
Mark G. Currie Ph.D. Senior Vice President, Chief Scientific Officer, President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Thomas A. McCourt Senior Vice President - Marketing and Sales, Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Halley E. Gilbert Esq. Senior Vice President, Chief Legal Officer, Secretary
Age: 45
Bio & Compensation  - Reuters
George H. Conrades Independent Director
Age: 76
Bio & Compensation  - Reuters
Joseph C. Cook Jr. Independent Director
Age: 73
Bio & Compensation  - Reuters
David A. Ebersman Independent Director
Age: 45
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 61
Bio & Compensation  - Reuters